SEC Tracker
Get the app

Bio-Rad Laboratories BIO

Bio-Rad Laboratories Q1 FY26: revenue $592.1M, up 1%; diluted EPS −$19.55

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Bio-Rad Laboratories reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$592.1M+1% from $585.4M in Q1 FY2510-Q income statement, on EDGAR
  2. Net income−$527.1M−924% from $64.0M in Q1 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$19.55−954% from $2.29 in Q1 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$507.2M−3% from $521.4M in Q1 FY25Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations$108.1M−17% from $129.9M in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Bio-Rad Laboratories files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3826 and related industry codes: the same peer list as the financial tables.

  1. Ralliant RAL public float $3.0B, Feb 23, 2026
  2. Itron ITRI public float $5.9B, Jun 30, 2025
  3. Revvity RVTY public float $11.3B, Jun 28, 2025
  4. Vontier VNT public float $5.4B, Jun 27, 2025
  5. Bruker BRKR public float $4.3B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.